Roth Comments on ImmunoCellular (IMUC) Following ICT-107 Updates; Affirms 'Buy' Rating
Tweet Send to a Friend
Roth Capital affirms its Buy rating and $3 target price on ImmunoCellular Therapeutics (NYSE: IMUC) following expectations of positive FDA ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
